Celldex Reports Strong Retreatment Results With Barzolvolimab In Cold Urticaria and Symptomatic Dermographism

on

Celldex presented Phase 2 open-label extension data at the 2026 AAAAI Annual Meeting showing barzolvolimab retreatment produces rapid, profound efficacy similar to initial treatment in cold urticaria and symptomatic dermographism12

Complete response rates at Week 20 were 62% for cold urticaria and 60% for symptomatic dermographism, consistent with first-time treatment results2

Retreatment achieved clinically meaningful improvements with up to 68% of cold urticaria patients and 69% of symptomatic dermographism patients achieving well-controlled disease2

Barzolvolimab is a humanized monoclonal antibody that uniquely targets mast cells, the root cause of these chronic skin conditions13

The drug was well tolerated with a safety profile consistent with earlier studies1

Marked, rapid reductions in critical temperature and friction thresholds were observed upon retreatment2

The ability to retreat demonstrates potential for intermittent therapy to manage recurring symptoms in real-world treatment approaches1

A global Phase 3 program called EMBARQ is underway to further evaluate barzolvolimab in cold urticaria and symptomatic dermographism1

Sources:

1. https://www.nasdaq.com/articles/celldex-reports-strong-retreatment-results-barzolvolimab-cold-urticaria-and-dermographism

2. https://www.stocktitan.net/news/CLDX/celldex-presents-positive-data-demonstrating-barzolvolimab-4c1w4bsj5mg1.html

3. https://www.globenewswire.com/news-release/2026/02/27/3246759/0/en/Celldex-Presents-Additional-Positive-Data-from-Phase-2-Chronic-Spontaneous-Urticaria-CSU-and-Phase-2-Cold-Urticaria-ColdU-and-Symptomatic-Dermographism-SD-Studies-Further-Demonstra.html